XML 46 R37.htm IDEA: XBRL DOCUMENT
v3.25.1

License Agreements - Additional Information (Details) - USD ($) |  | 1 Months Ended | 3 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | ---
Mar. 28, 2022 | Jan. 31, 2023 | Oct. 31, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Apr. 30, 2020 | Mar. 31, 2025 | Mar. 31, 2024 | Dec. 31, 2024 | Mar. 31, 2023 | Oct. 06, 2022
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  | $ 17,044,000 | $ 13,029,000 |  |  |
Common stock, shares issued |  |  |  |  |  |  | 61,631,376 |  | 59,967,814 |  |
Common Stock, Value, Issued |  |  |  |  |  |  | $ 62,000 |  | $ 60,000 |  |
Pfizer License Agreement |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payment for license fee |  |  |  | $ 25,000,000 |  |  |  |  |  |  |
Common stock, shares issued |  |  |  |  |  |  |  |  |  | 1,811,594 | 2,229,654
Milestone and royalties required |  |  |  |  |  |  | 0 | 0 |  |  |
Upfront payments |  | $ 8,000,000 |  | $ 5,000,000 |  |  |  |  |  |  |
Pfizer License Agreement | IPO |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of common shares issued upon conversion of preferred stock |  |  | 1,911,015 |  |  |  |  |  |  |  |
Pfizer License Agreement | Series B Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Issuance of convertible preferred stock shares |  |  | 12,152,145 |  |  |  |  |  |  |  |
Issuance of convertible preferred stock value |  |  | $ 20,000,000 |  |  |  |  |  |  |  |
Biosion License Agreement |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone and royalties required |  |  |  |  |  |  | 0 | 0 |  |  |
Biosion License Agreement | Research and Development Expenses |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront fee | $ 10,000,000 |  |  |  |  |  |  |  |  |  |
Simcere License Agreement |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Royalty obligation period for licensed products upon after first commercial sale |  |  |  |  | 15 years |  |  |  |  |  |
Milestone and royalties receivable |  |  |  |  |  |  | 0 |  |  |  |
Mabwell Agreement |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone and royalties receivable |  |  |  |  |  |  | 0 |  |  |  |
Toray Sublicense Agreement |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone and royalties receivable |  |  |  |  |  |  | 0 |  |  |  |
University License Agreement |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Common stock issued to university |  |  |  |  |  | 48,919 |  |  |  |  |
Milestone and royalties required |  |  |  |  |  |  | $ 0 | $ 0 |  |  |

X
- Definition Common stock issued to university. + References No definition available. + Details
Name: | pyxs_CommonStockIssuedToUniversity
Namespace Prefix: | pyxs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Convertible preferred stock shares issued value. + References No definition available. + Details
Name: | pyxs_ConvertiblePreferredStockSharesIssuedValue
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Issuance of convertible preferred stock shares. + References No definition available. + Details
Name: | pyxs_IssuanceOfConvertiblePreferredStockShares
Namespace Prefix: | pyxs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone and royalties incurred. + References No definition available. + Details
Name: | pyxs_MilestoneAndRoyaltiesIncurred
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone and royalties receivable. + References No definition available. + Details
Name: | pyxs_MilestoneAndRoyaltiesReceivable
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of common shares issued upon conversion of preferred stock. + References No definition available. + Details
Name: | pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock
Namespace Prefix: | pyxs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment for license fee. + References No definition available. + Details
Name: | pyxs_PaymentForLicenseFee
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty obligation period for licensed products upon after first commercial sale. + References No definition available. + Details
Name: | pyxs_RoyaltyObligationPeriodForLicensedProductsUponAfterFirstCommercialSale
Namespace Prefix: | pyxs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront fee. + References No definition available. + Details
Name: | pyxs_UpfrontFee
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payments. + References No definition available. + Details
Name: | pyxs_UpfrontPayments
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details
Name: | us-gaap_CommonStockValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=pyxs_BiosionLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=pyxs_SimcereLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=pyxs_MabwellAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=pyxs_ToraySublicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |